NASDAQ: CCCCC4 Therapeutics Inc Stock
$2.66-0.07 (-2.56%)
Updated Sep 12, 2025
CCCC Price
$2.66
Fair Value Price
N/A
Market Cap
$189.31M
52 Week Low
$1.09
52 Week High
$7.14
P/E
-1.68x
P/B
1.09x
P/S
2.97x
PEG
N/A
Dividend Yield
N/A
Revenue
$34.24M
Earnings
-$111.58M
Gross Margin
100%
Operating Margin
-325.5%
Profit Margin
-325.9%
Debt to Equity
0.7
Operating Cash Flow
-$87M
Beta
1.88
Next Earnings
Oct 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CCCC Overview
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies to degrade disease-causing proteins and thereby treat cancer, neurodegenerative conditions, and other diseases. The company uses its TORPEDO platform to synthesize targeted small molecule protein degraders, which employ a natural protein disposal system to catalyze the destruction of target proteins. C4 Therapeutics has strategic collaborations with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2015 and is headquartered in Watertown, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CCCC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CCCC
Ranked#293 of 476
Ranked#293 of 476
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.30 | A | |
| $37.96 | A | |
| $7.91 | A |
Be the first to know about important CCCC news, forecast changes, insider trades & much more!
CCCC News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CCCC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CCCC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CCCC is good value based on its book value relative to its share price (1.09x), compared to the US Biotechnology industry average (4.65x)
P/B vs Industry Valuation
CCCC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CCCC due diligence checks available for Premium users.
Valuation
CCCC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.68x
Industry
-97.08x
Market
36.96x
CCCC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.09x
Industry
4.65x
CCCC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CCCC's financial health
Profit margin
Revenue
$6.5M
Net Income
-$26.0M
Profit Margin
-402.6%
CCCC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CCCC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$296.5M
Liabilities
$122.5M
Debt to equity
0.7
CCCC's short-term assets ($224.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CCCC's short-term assets ($224.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CCCC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CCCC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.1M
Investing
$38.9M
Financing
$0.0
CCCC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CCCC vs Biotech Stocks
C4 Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.